Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SP-01 (Sancuso) in CINV
NCT01937156Phase 3Completed
- Sponsor
- Solasia Pharma
- Start
- Aug 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of granisetron in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Solasia Pharma. Primary endpoint: Percentage of subjects achieving Complete Control (CC) of CINV at 7 days. Started Aug 2013; status: completed.
02
Drugs
granisetron
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01937156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01937156.